The efficacy, safety and tolerability of Circadin® have been reported in several key publications.
In this section you will find a list of the major publications. Please note that Circadin® is indicated as monotherapy for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over. Accordingly, the off label use which may be indicated in the articles below is not recommended by Neurim and the prescribing and labelling of your country must be followed.
In this section you will find a list of the major publications. Please note that Circadin® is indicated as monotherapy for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over. Accordingly, the off label use which may be indicated in the articles below is not recommended by Neurim and the prescribing and labelling of your country must be followed.
To view an abstract, simply click on the title of the publication.
Insomnia
- Sleep and sleep disturbances: biological basis and clinical implications
Zisapel N - Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviours
Morin CM, LeBlanc M, Daley M, Gregoire JP, Mérette C - Insomnia: definition, prevalence, etiology, and consequences
Roth T - British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders
Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG
Melatonin and sleep
- Role of melatonin in the regulation of human circadian rhythms and sleep
Cajochen C, Kräuchi K, Wirz-Justice A - Melatonin and aging: prospects for human treatment
Bubenik GA, Konturek SJ - Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy
Leger D, Laudon M, Zisapel N - Prolonged-release melatonin for the treatment of insomnia: targeting Quality of Sleep and morning alertness
Wade AG, Zisapel N, Lemoine P - Melatonin–Dopamine interactions: from basic neurochemistry to a clinical setting
Zisapel N - Sleep and sleep disorders in older adults
Crowley K - Sleep disorders in the older adult – a mini-review
Neikrug AB, Ancoli-Israel S
Sleep quality vs. sleep quantity
- Prevalence and correlates of nonrestorative sleep complaints
Ohayon MM - Sleep quality versus sleep quantity: relationships between sleep quality and measures of health, well-being and sleepiness in college students
Pilcher JJ, Ginter DR, Sadowsky B - Sleep and sleep disturbances: biological basis and clinical implications
Zisapel N - Prolonged-release melatonin for the treatment of insomnia: targeting Quality of Sleep and morning alertness
Wade AG, Zisapel N, Lemoine P
Sleep problems in elderly
- Identification and treatment of sleep problems in the elderly
Ancoli-Israel S, Poceta JS, Stepnowsky C, Martin J, Gehrman P - Management of chronic insomnia in elderly persons
Bain KT - Improvement of sleep quality in elderly people by controlled-release melatonin
Garfinkel D, Laudon M, Nof D, Zisapel N - The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia
Luthringer R, Muzet M, Zisapel N, Staner L
Traditional sleep drugs: use and abuse
- Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE - The use of benzodiazepines in the aged patient: clinical and pharmacological considerations
Dailly E, Bourin M - Association between benzodiazepines and recurrent falls: a cross-sectional elderly population-based study
Rossat A, Fantino B, Bongue B, Colvez A, Nitenberg C, Annweiler C, Beauchet O - The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies
Riemann D, Perlis ML - Hypnotics’ association with mortality or cancer: a matched cohort study
Kripke D, Langer R, Kline L - Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries
Clay E, Falissard B, Moore N, Toumi M
Circadin® main studies
- Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: Quality of Sleep and next-day alertness outcomes
Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N - Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects
Lemoine P, Nir T, Laudon M, Zisapel N - Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response
Wade AG, Crawford G, Ford I, McConnachie A, Nir T, Laudon M, Zisapel N - Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N - Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N - Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin
Hajak G, Lemme K, Zisapel N
Circadin® vs. traditional sleep drugs
- Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers
Otmani S, Demazières A, Staner C, Jacob N, Nir T, Zisapel N, Staner L - Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach
Garfinkel D, Zisapel N, Wainstein J, Laudon M - Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database
Kunz D, Bineau S, Maman K, Milea D, Toumi M - Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam
Paul MA, Gray G, MacLellan M, Pigeau RA - Melatonin and zopiclone as facilitators of early circadian sleep in operational air transport crews
Paul MA, Gray G, Sardana TM, Pigeau RA
Circadin® in mental disorders and conditions
- Melatonin for the treatment of sleep disturbances in major depressive disorder
Dolberg OT, Hirschmann S, Grunhaus L - Melatonin improves sleep quality of patients with chronic schizophrenia
Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N - Effect of controlled-release melatonin on sleep quality, mood, and Quality of Life in subjects with seasonal or weather-associated changes in mood and behaviour
Leppämäki S, Partonen T, Vakkuri O, Lönnqvist J, Partinen M, Laudon M
Circadin® in children
- Prolonged-release melatonin for children with neurodevelopmental disorders
De Leersnyder H, Zisapel N, Laudon M - Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders
Jan JE, Hamilton D, Seward N, Fast DK, Freeman RD, Laudon M
Circadin® in diabetes
- Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study
Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N
Circadin® in hypertension
- Impaired nocturnal melatonin secretion in non-dipper hypertensive patients
Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E - Melatonin reduces night blood pressure in patients with nocturnal hypertension
Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, Kamari Y, Shen-Orr Z,
Zisapel N - Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials
Grossman E, Laudon M, Zisapel N
Circadin® in Alzheimer
- Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A, Zisapel N
